Return to site

SynMetabio Secures Multi-Million RMB Funding for Bio-Based Leather Production

Investment to Accelerate Expansion of Naro, a Unique 100% Bio-Based Leather Material, and Team Development

March 8, 2023

SynMetabio, a synthetic biology company, recently completed a seed round and angel round financing of several tens of millions of RMB. This funding will be used to expand the production of Naro, a 100% bio-based leather material, and to build the team.

 

Naro, developed by SynMetabio, is a 100% bio-based raw material leather with unique biological texture and plasticity. Through engineered design, microorganisms assemble and crystallize countless fiber chains during their growth, ultimately forming an ultra-fine network structure similar to collagen protein in nanoscale. SynMetabio has established a stable production amplification system by screening and modifying microorganisms. The fibers are then combined with degradable natural materials and supplemented with natural fibers for the recycling of natural fibers and the mimicking of natural elements, resulting in Naro, a high-quality and environmentally friendly 100% bio-based leather. It is known that SynMetabio has already conducted pilot production of Naro at a scale of hundreds of liters.

 

Based on different application scenarios and customer requirements, SynMetabio's product development team treats the materials differently to change their form and optimizes their physical and chemical properties, texture, and touch, among other parameters, to achieve personalized customization of bio-based materials. Currently, SynMetabio is able to provide downstream customers with various performance leather and fiber materials.

 

 

Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.